006 is the extension study of 002. Ideally they want long-term data from at least 750 out of the 938 participants that start the 002 trial but it’s hard to know exactly how many will remain 12+ months from now. So they’ve simply assumed a 20% attrition rate for the 002 trial due to covid and other reasons for conservatism.
Pfizer's Tanezumab receives almost unanimous rejection by FDA Adcom, page-16
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.005(1.96%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 25.0¢ | $13.08K | 51.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 133489 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 25012 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |